Ministry of Health launches probe, questions 2 doctors over promotion of exosome injections

Saudi Arabia's Ministry of Health has launched an investigation into the alleged promotion and use of exosome injections, citing potential violations of ministry regulations. The ministry confirmed it has initiated legal proceedings and is actively questioning the two doctors implicated in the matter.

Officials emphasized that all healthcare practices and services must strictly comply with officially approved licenses and accreditations. The ministry also clarified that cosmetic products intended for external use require specific approvals and accreditations before they can be marketed as medical treatments or administered intravenously. This directive aims to ensure adherence to established bylaws governing healthcare operations.

Patient safety is paramount, the ministry stated, underscoring the need for strict adherence to approved scientific and regulatory standards. Healthcare practitioners were reminded of their professional ethics and responsibilities in maintaining the quality of care and safeguarding patients. The investigation underscores the ministry's commitment to oversight within the healthcare sector.

Exosome therapy, a regenerative treatment, utilizes tiny vesicles released by mesenchymal stem cells. These vesicles deliver therapeutic components like growth factors and anti-inflammatory signals to damaged tissues, promoting repair without cell transplantation. The therapy is noted for its pre-manufactured nature, allowing for same-day administration.